pulrodemstat

Pulrodemstat (CC-90011) is a potent, selective, reversible, and orally active small molecule inhibitor of lysine-specific demethylase 1 (LSD1). By inhibiting LSD1, it increases the expression of tumor-suppressing genes and decreases the expression of tumor-promoting genes, leading to reduced tumor cell growth. Pulrodemstat has demonstrated clinical activity in patients with advanced solid tumors and relapsed/refractory lymphoma, particularly neuroendocrine neoplasms. The drug was originally developed by Quanticel Pharmaceuticals and further developed by Celgene. It has been evaluated in phase I/II trials for various cancers including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), non-Hodgkin lymphoma, acute myeloid leukemia (AML), prostate cancer, and other solid tumors.

Other names

pulrodemstat